hr-810 and Bronchitis

Twenty two patients with inflammatory respiratory tract infection were treated with cefpirome. Among the patients 14 were with severe pneumonia, 4 with exacerbated obstructive chronic purulent bronchitis and 4 with mucoviscidosis. All the patients were subjected to clinical, laboratory and x-ray examinations, electrocardiography, estimation of the external respiration and sputum bacteriological tests. The cefpirome susceptibility was determined by the agar diffusion assay with standard disks from Roussel Uclaf. Cefpirome was administered by slow intravenous infusion in a daily dose of 2 to 4 g every 12 hours depending on the disease severity. After 2 or 3 days of the patient afebrile temperature and normal differential blood count the therapy was discontinued. The favourable time course of the disease was recorded in 12 out of the 14 patients with pneumonia. Recovery and clinical improvement were stated in 64.3 and 21.4 per cent of the cases respectively. In 2 patients the treatment failed. In all the patients with exacerbated severe chronic purulent bronchitis the cefpirome therapy resulted in the disease remission. The clinical effect of the mucoviscidosis treatment was observed in 3 out of the 4 patients. The drug tolerance in the doses used was good.

Topics: Adolescent; Adult; Aged; Bacterial Infections; Bronchitis; Cefpirome; Cephalosporins; Chronic Disease; Cystic Fibrosis; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Pneumonia, Bacterial; Pseudomonas aeruginosa; Staphylococcus; Treatment Outcome

Twenty patients with lower respiratory tract infection were treated with cefpirome: 16 patients with pneumonia and 4 patients with chronic bronchitis which developed at the background of other diseases such as chronic somatic diseases, lung cancer, exudative pleurisy and others. The drug was administered intravenously in a dose of 1 g twice a day for 7 to 10 days. The clinical efficacy was stated in 80 per cent of the cases. In 95 per cent of the cases the drug tolerance was good. The isolates from the patients were susceptible to cefpirome in 83 per cent of the cases.

Topics: Adult; Bacterial Infections; Bronchitis; Cefpirome; Cephalosporins; Chronic Disease; Female; Humans; Male; Microbial Sensitivity Tests; Pneumonia, Bacterial; Treatment Outcome

The clinical efficacy and tolerance of cefpirome were estimated in the treatment of patients with bacterial infection of the respiratory tract. The estimate included 15 patients with acute and chronic bronchopulmonary diseases: 6 patients with acute pneumonia, 5 with exacerbated chronic purulent obstructive bronchitis and 4 with primary immune deficiency (agammaglobulinemia and acute pneumonia). Excellent and good total efficacy of the drug was stated in 6 and 8 patients respectively. In 1 patient the treatment was discontinued because of acute urticaria. Therefore, cefpirome is to be recommended as a highly efficient agent for the treatment of bronchopulmonary infection.

Topics: Acute Disease; Adolescent; Adult; Agammaglobulinemia; Bacterial Infections; Bronchitis; Cefpirome; Cephalosporins; Female; Humans; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome

Cefpirome (HR 810, CPR), a new cephem antibiotic, was investigated for its experimental and clinical studies in pediatrics. The results obtained are summarized as follows. 1. Plasma and urinary levels of CPR were determined in 2 children (age 5 and 7 years) after the one shot intravenous injection of the drug at 20 mg/kg. Average plasma levels of the drug were 44.7 micrograms/ml, 28.5 micrograms/ml, 10.5 micrograms/ml, 4.6 micrograms/ml and 1.5 micrograms/ml at 1/2 hour, 1 hour, 2 hours, 4 hours and 6 hours, respectively, and the average half life was 1.57 hours. Average urinary levels of the drug were 1,785 micrograms/ml, 545 micrograms/ml and 198 micrograms/ml at 0-2 hours, 2-4 hours, 4-6 hours, respectively and the average urinary elimination rate was 52.0%. The results were nearly equivalent to those in adults except for urinary elimination rate which tended to be slightly lower than that in adults. 2. Cerebrospinal fluid levels in 3 cases of purulent meningitis treated with CPR were investigated. Cerebrospinal fluid levels in a case of Neisseria meningitidis were 11.5-23.1 micrograms/ml at 1 hour and 0.94 microgram/ml at 5 hours after intravenous injection of 44.4 mg/kg, 4 times a day. Cerebrospinal fluid levels in a case of Streptococcus pneumoniae were 1.01-4.23 micrograms/ml at 1 hour after intravenous injection of 49.0 mg/kg, 6 times a day, and in the other case with Streptococcus pneumoniae, the levels were 16.8-37.1 micrograms/ml at 1 hour, 11.3 and 3.60 micrograms/ml at 3 and 4 hours after intravenous injection 52.2 mg/kg, 6 times a day. These results are not inferior to those with cefotaxime or ceftriaxone. These levels appear to be higher than MIC90 values against Escherichia coli, Streptococcus agalactiae, S. pneumoniae or Haemophilus influenzae which are the major pathogens of these diseases. 3. CPR was given to 62 patients and clinical efficacy, bacteriological response and adverse reactions were evaluated. Evaluated cases for clinical efficacy included 3 cases of purulent meningitis, 1 case of acute purulent otitis media, 2 cases of acute purulent tonsillitis, 1 case of acute bronchitis, 49 cases of acute pneumoniae, 1 case of scarlet fever, 1 case of acute osteomyelitis, 1 case of acute enterocolitis, and 2 cases of acute UTI, totalling 61 cases. Clinical efficacies were excellent in 38 cases, good in 22 cases and fair in 1 case with an efficacy rete of 98.4% (excellent + good).(ABSTRACT TRUNCATED AT 400 WORDS)

Topics: Acute Disease; Adolescent; Bacterial Infections; Bronchitis; Cefpirome; Cephalosporins; Child; Child, Preschool; Enterocolitis; Female; Humans; Infant; Male; Meningitis; Osteomyelitis; Otitis Media; Pneumonia; Scarlet Fever; Tonsillitis; Urinary Tract Infections